A genetic score combining CYP450 2C19 and 3A4 genotypes to predict voriconazole plasma exposure?
Laboratoire de Pharmacologie-Toxicologie, Centre Hospitalier Universitaire Grenoble Alpes, CS 10217, Grenoble CEDEX 9 F-38043, France. Electronic address: egautier@chu-grenoble.fr.
Elodie
E
Gautier-Veyret
Laboratoire de Pharmacologie-Toxicologie, Centre Hospitalier Universitaire Grenoble Alpes, CS 10217, Grenoble CEDEX 9 F-38043, France.
Xavier
X
Fonrose
Laboratoire de Pharmacologie-Toxicologie, Centre Hospitalier Universitaire Grenoble Alpes, CS 10217, Grenoble CEDEX 9 F-38043, France.
Françoise
F
Stanke-Labesque
D000935:Antifungal Agents / Q000493:pharmacokinetics*; D065731:Cytochrome P-450 CYP2C19 / Q000235:genetics*; D051544:Cytochrome P-450 CYP3A / Q000235:genetics*; D065692:Cytochrome P-450 CYP3A Inhibitors / Q000494:pharmacology*; D005838:Genotype; D006801:Humans; D010949:Plasma / Q000737:chemistry*; D065819:Voriconazole / Q000493:pharmacokinetics*
D000935:Antifungal Agents; D065692:Cytochrome P-450 CYP3A Inhibitors; C045793:CYP2C19 protein, human; D065731:Cytochrome P-450 CYP2C19; D051544:Cytochrome P-450 CYP3A; C510163:CYP3A4 protein, human; D065819:Voriconazole